On January 16, 2026, Junlin Ho, serving as General Counsel for Scholar Rock Holding Corp (NASDAQ:SRRK), disclosed the sale of 8,016 shares of common stock via a Securities and Exchange Commission Form 4 filing. The shares were transacted at a unit price of $44.4777, resulting in gross proceeds of $356,533.
Post-sale, Ho retains direct ownership in the company encompassing 214,553 shares in total. This includes 121,471 held as common stock and an additional 93,082 represented by restricted stock units (RSUs).
The decision to divest these shares was aimed at covering tax withholding obligations prompted by the vesting of RSUs on January 15, 2026, facilitating compliance with fiscal responsibilities tied to employee equity compensation.
Concurrently, Scholar Rock continues to progress amidst a mix of analyst interest and operational challenges. UBS recently commenced coverage on the stock with a Buy rating and set a price target at $60, emphasizing the promise of apitegromab, the company's leading therapeutic candidate. Cantor Fitzgerald maintained an Overweight rating, affirming optimism regarding regulatory approval prospects, specifically for apitegromab's potential in treating spinal muscular atrophy.
However, the company faces regulatory hurdles as well; their manufacturing partner, Catalent Indiana, received a warning letter from the FDA. Scholar Rock plans to address these issues and aims to resubmit its biologics license application in 2026, underlining ongoing compliance efforts.
Analyst Wolfe Research launched coverage with an Outperform rating and a $42 price target notwithstanding a recent FDA Complete Response Letter setback relating to apitegromab. Additionally, BMO Capital increased its price target from $45 to $50 and sustained an Outperform rating, noting accelerated technology transfer to a second manufacturing site intended to secure sufficient commercial production capacity.
These developments illustrate dynamic movements within Scholar Rock as it endeavors to secure market approval and commercial scalability for its lead compound, amidst regulatory scrutiny and evolving analyst evaluations.